1887
Volume 2025, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

This umbrella review aims to synthesize evidence from previously conducted meta-analyses and review articles to assess the effects of bempedoic acid on lipid profile and cardiovascular events.

While adhering to the Preferred Reporting Items for Overviews of Reviews guidelines, PubMed, Google Scholar, Web of Science, and Scopus were searched from the database inception to June 2024 to identify relevant articles. The outcomes were total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol, triglyceride (TAG), apolipoprotein B (APOB), high-sensitivity CRP (hs-CRP), major cardiovascular events (MACE), cardiovascular mortality, and myocardial infarction (MI). A corrected covered area (CCA) assessment was performed to determine overlap among reviews. Each included review was assessed for its quality and rigor via the AMSTAR-2 tool.

From 18,297 articles identified during the literature search, 18 meta-analyses were included. A significant overlap was noted across studies with a corrected cover area of 44.4%. Bempedoic acid’s effects on cardiovascular outcomes and lipid levels have been extensively studied. For cardiovascular mortality, the evidence is mixed: Goyal et al.21 reported a risk ratio (RR) of 0.81 (95% CI 0.61–1.08) suggesting a potential benefit, while other studies, such as De Filippo et al.26 and Zhang et al.24, indicate no significant association. In terms of MACE, 11 reviews show a consistent trend toward reduced risk, with RRs between 0.75 and 0.88. Bempedoic acid also appears to significantly reduce the risk of MI, with RRs and odds ratios (ORs) around 0.76. Evidence on unstable angina suggests a lower risk, although some studies do not reach statistical significance. For coronary revascularization, the data show a reduced risk, with RRs ranging from 0.74 to 0.82. Studies on coronary non-revascularization also indicate a significant risk reduction with RRs and ORs of 0.41. Regarding lipid levels, bempedoic acid consistently reduces LDL cholesterol (mean differences [MDs] from −17.5% to −33.91%), total cholesterol (MDs from −12.69% to −34.41%), and non-HDL cholesterol (MDs from −12.3% to −23.27%). The effects on HDL cholesterol are less consistent (MDs from −1.29% to −5.18%), and triglyceride levels show variable results (MDs from −8.35% to +5.23%).

Our findings show that bempedoic acid significantly reduces the risk of MACE, nonfatal MI, coronary and noncoronary revascularization, and hospitalizations for unstable angina. While results on cardiovascular mortality are mixed, suggesting a need for further study, bempedoic acid proves to be an effective treatment for improving lipid profiles and reducing cardiovascular events, especially in patients who cannot tolerate statins. It presents a valuable option for cardiovascular risk management, potentially enhancing patient outcomes and quality of life. Further research is needed to assess its long-term benefits and broader applicability.

© 2025 Ali, Bhimani, Karmani, Dhillon, Saeed, Amir, et al., licensee HBKU Press.
Loading

Article metrics loading...

/content/journals/10.5339/qmj.2025.51
2025-06-30
2025-12-14

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/qmj/2025/2/qmj.2025.51.html?itemId=/content/journals/10.5339/qmj.2025.51&mimeType=html&fmt=ahah

References

  1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020; 141:(9):e139–596. https://doi.org/10.1161/CIR.0000000000000757
     [Google Scholar]
  2. Albosta M, Grant JK, Michos ED. Bempedoic acid: lipid lowering for cardiovascular disease prevention. Heart Int. 2023 Nov 1; 17:(2):27–34. https://doi.org/10.17925/HI.2023.17.2.1
     [Google Scholar]
  3. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255. https://doi.org/10.1093/eurheartj/ehz826]. Eur Heart J. 2020; 41:(1):111–88. https://doi.org/10.1093/eurheartj/ehz455
     [Google Scholar]
  4. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Circulation. 2019 Jun 18;139(25):e1178–81. https://doi.org/10.1161/CIR.0000000000000699]. Circulation. 2019; 139:(25):e1046–81. https://doi.org/10.1161/CIR.0000000000000624
     [Google Scholar]
  5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333:(20):1301–7. https://doi.org/10.1056/NEJM199511163332001
     [Google Scholar]
  6. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279:(20):1615–22. https://doi.org/10.1001/jama.279.20.1615
     [Google Scholar]
  7. Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022; 16:(4):361–75. https://doi.org/10.1016/j.jacl.2022.05.068
     [Google Scholar]
  8. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019; 4:(3):206–13. https://doi.org/10.1001/jamacardio.2018.4936
     [Google Scholar]
  9. De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014; 78:(4):684–98. https://doi.org/10.1111/bcp.12339
     [Google Scholar]
  10. Banach M, Penson PE. Lipid-lowering therapies: better together. Atherosclerosis. 2021; 320:86–8. doi: [Crossref]
     https://doi.org/10.1016/j.atherosclerosis.2021.01.009 [Google Scholar]
  11. Banach M, Penson PE. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER? Cardiovasc Res. 2019; 115:(3):e26–31. https://doi.org/10.1093/cvr/cvy301
     [Google Scholar]
  12. Henney NC, Banach M, Penson PE. RNA silencing in the management of dyslipidemias. Curr Atheroscler Rep. 2021; 23:(11):69. https://doi.org/10.1007/s11883-021-00968-7
     [Google Scholar]
  13. Penson P, McGowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opin Investig Drugs. 2017; 26:(2):251–9. https://doi.org/10.1080/13543784.2017.1280458
     [Google Scholar]
  14. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016; 7:13457. https://doi.org/10.1038/ncomms13457
     [Google Scholar]
  15. Ballantyne CM, Davidson MH, Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013; 62:(13):1154–62. https://doi.org/10.1016/j.jacc.2013.05.050
     [Google Scholar]
  16. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023; 388:(15):1353–64. https://doi.org/10.1056/NEJMoa2215024
     [Google Scholar]
  17. Pollock M, Fernandes RM, Pieper D, Tricco AC, Gates M, Gates A, et al. Preferred reporting items for overviews of reviews (Prior): a protocol for the development of a reporting guideline for overviews of reviews of healthcare interventions. Syst Rev. 2019; 8:(1):335. https://doi.org/10.1186/s13643-019-1252-9
     [Google Scholar]
  18. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both. BMJ (Clinical Res ed). 2017; 358:j4008. https://doi.org/10.1136/bmj.j4008
     [Google Scholar]
  19. Pieper D, Antoine S-L, Mathes T, Neugebauer EAM, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. Clin Epidemiol. 2014; 67:(4):368–75. https://doi.org/10.1016/j.jclinepi.2013.11.007
     [Google Scholar]
  20. Del Carpio-Tenorio C, Llerena-Velastegui J, Villacis-Lopez C, Placencia-Silva M, Santander-Fuentes C, Benitez-Acosta K, et al. Impact of bempedoic acid on LDL-C reduction and cardiovascular outcomes: a comprehensive meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024 Feb; 49:(2):102191. https://doi.org/10.1016/j.cpcardiol.2023.102191
     [Google Scholar]
  21. Goyal A, Changez MIK, Tariq MD, Mushtaq F, Shamim U, Sohail AH, et al. Efficacy and outcomes of bempedoic acid versus placebo in patients with statin-intolerance: a pilot systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2024 Feb; 49:(2):102236. https://doi.org/10.1016/j.cpcardiol.2023.102236
     [Google Scholar]
  22. Li Y, Gao H, Zhao J, Ma L, Hu D. Safety and efficacy of bempedoic acid among patients with statin intolerance and those without: a meta-analysis and a systematic randomized controlled trial review. PLoS One. 2024 Jan 26; 19:(1):e0297854. https://doi.org/10.1371/journal.pone.0297854
     [Google Scholar]
  23. Venkatraman S, Das S, Eerike M, Cherian JJ, Bagepally BS. Efficacy and safety of bempedoic acid lipid-lowering therapy: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2023 Nov; 79:(11):1453–63. https://doi.org/10.1007/s00228-023-03555-8
     [Google Scholar]
  24. Zhang J, Guan X, Zhang B, Wang J, Jin X, Zhao Y, et al. Bempedoic acid can reduce cardiovascular events in combination with statins or as monotherapy: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2023 Nov; 23:(6):695–708. https://doi.org/10.1007/s40256-023-00606-4
     [Google Scholar]
  25. Uddin N, Syed AA, Ismail SM, Ashraf MT, Khan MK, Sohail A. Clinical efficacy and safety of bempedoic acid in high cardiovascular risk patients: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol. 2023 Dec; 48:(12):102003. https://doi.org/10.1016/j.cpcardiol.2023.102003
     [Google Scholar]
  26. De Filippo O, D’Ascenzo F, Iannaccone M, Bertaina M, Leone A, Borzillo I, et al. Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials. Cardiovasc Diabetol. 2023 Nov 28; 22:(1):324. https://doi.org/10.1186/s12933-023-02022-z
     [Google Scholar]
  27. Mutschlechner D, Tscharre M, Huber K, Gremmel T. Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20; 9:(6):583–91. https://doi.org/10.1093/ehjcvp/pvad052
     [Google Scholar]
  28. Lin Y, Parco C, Karathanos A, Krieger T, Schulze V, Chernyak N, et al. Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis. BMJ Open. 2022 Feb 24; 12:(2):e048893. https://doi.org/10.1136/bmjopen-2021-048893
     [Google Scholar]
  29. Masson W, Lobo M, Lavalle-Cobo A, Molinero G. Effect of bempedoic acid on atherogenic lipids and inflammation: a meta-analysis. Clin Investig Arterioscler. 2021 May–Jun; 33:(3):117–26. https://doi.org/10.1016/j.arteri.2020.09.002
     [Google Scholar]
  30. Dai L, Zuo Y, You Q, Poggio P, Forte F, Spadarella G, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2021 Jul 23; 28:(8):825–33. https://doi.org/10.1177/2047487320930585
     [Google Scholar]
  31. Wang X, Luo S, Gan X, He C, Huang R. Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Kardiol Pol. 2019; 77:(2):207–16. https://doi.org/10.5603/KP.a2019.0013
     [Google Scholar]
  32. Bhagavathula AS, Al Matrooshi NO, Clark CCT, Rahmani J. Bempedoic acid and ezetimibe for the treatment of hypercholesterolemia: a systematic review and meta-analysis of randomized phase II/III trials. Clin Drug Investig. 2021 Jan; 41:(1):19–28. https://doi.org/10.1007/s40261-020-00989-1
     [Google Scholar]
  33. Wang X, Zhang Y, Tan H, Wang P, Zha X, Chong W, et al. Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis. Cardiovasc Diabetol. 2020 Aug 12; 19:(1):128. https://doi.org/10.1186/s12933-020-01101-9
     [Google Scholar]
  34. Cicero AFG, Pontremoli R, Fogacci F, Viazzi F, Borghi C. Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies. Drug Saf. 2020 Aug; 43:(8):727–36. https://doi.org/10.1007/s40264-020-00931-6
     [Google Scholar]
  35. Khan MU, Khan MZ, Munir MB, Balla S, Khan SU. Meta-analysis of the safety and efficacy of bempedoic acid. Am J Cardiol. 2020 Sep 15; 131:130–2. https://doi.org/10.1016/j.amjcard.2020.06.028
     [Google Scholar]
  36. Cicero AFG, Fogacci F, Hernandez AV Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP). Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis. PLoS Med. 2020 Jul 16; 17:(7):e1003121. https://doi.org/10.1371/journal.pmed.1003121
     [Google Scholar]
  37. Di Minno A, Lupoli R, Calcaterra I, Poggio P, Forte F, Spadarella G, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020 Aug 4; 9:(15):e016262. https://doi.org/10.1161/JAHA.119.016262
     [Google Scholar]
  38. Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ, et al. Role of bempedoic acid in clinical practice. Cardiovasc Drugs Ther. 2021 Aug; 35:(4):853–64.
     [Google Scholar]
  39. Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P, et al. Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients. JAMA. 2023 Jul 11; 330:(2):131–40.
     [Google Scholar]
  40. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017 Sep 21; 377:(12): 1119–31.
     [Google Scholar]
  41. Gunn LH, McKay AJ, Feng A, Louie MJ, Ballantyne CM, Ray KK. Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. Atheroscler Plus. 2022 Aug 1; 49:20–7.
     [Google Scholar]
  42. Cordero A, Olmo RF, Badimon L, Santos-Gallego CG, Castellano JM, Fácila L, et al. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events. J Clin Lipidol. 2023 Sep 1; 17:(5):602–11.
     [Google Scholar]
  43. Sayed A, Shazly O, Slipczuk L, Krittanawong C, Baloch F, Virani SS. The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials. Cardiovasc Drugs Ther. 2024 Dec; 38:(6):1415–1420. https://doi.org/10.1007/s10557-023-07474-9. Epub 2023 Jun 1. PMID: [PubMed] PMCID:PMC11680617.
     [Google Scholar]
  44. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18; 372:(25):2387–97.
     [Google Scholar]
  45. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4; 376:(18):1713–22.
     [Google Scholar]
  46. Ennezat PV, Guerbaai RA, Maréchaux S, Le Jemtel TH, François P. Extent of low-density lipoprotein cholesterol reduction and all-cause and cardiovascular mortality benefit: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2023 Jan 1; 81:(1):35–44.
     [Google Scholar]
  47. Grupp SA, Corbacioglu S, Kang HJ, Teshima T, Khaw SL, Locatelli F, et al. Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. Lancet Haematol. 2023 May 1; 10:(5):e333–45.
     [Google Scholar]
  48. Bhandari A, Oli PR, Shrestha DB, Pathak BD, Bhandari M, Sedhai YR, et al. Clinical efficacy and safety outcomes of bempedoic acid: an updated systematic review and meta-analysis after CLEAR outcomes trial. Health Sci Rev. 2023 Sep 16; 9:100116.
     [Google Scholar]
  49. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prevent Cardiol. 2020 Apr; 27:(6):593–603.
     [Google Scholar]
/content/journals/10.5339/qmj.2025.51
Loading
Evaluating the effects of bempedoic acid on lipid profiles and cardiovascular risk: An umbrella review of meta-analyses
Qatar Medical Journal 2025, 51 (2025); https://doi.org/10.5339/qmj.2025.51
/content/journals/10.5339/qmj.2025.51
/content/journals/10.5339/qmj.2025.51
Loading

Data & Media loading...

  • Article Type: Review Article
Keyword(s): Bempedoic acid, lipid profile and major adverse cardiovascular events

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error